US4483864A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Non-classical topical treatment for glaucoma
Assignee: University of Iowa Research Foundation
•
Filing: 1983-02-04
•
Granted: 1984-11-20
•
Expires: 2003-02-04
Abstract
Abstract A topical composition for eye treatment of glaucoma, comprising a small but pharmaceutically effective amount of a non-classical carbonic anhydrase inhibitor. The most preferred compound is methyl acetazolamide. The invention also relates to a method of topically treating glaucoma with eye drops of a non-classical carbonic anhydrase inhibitor to reduce intraocular pressure.
Inventors
- 👤 Charles F. Barfknecht
- 👤 Ronald D. Schoenwald
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 02:46
CPC Classifications
C; C07; C07D; C07D285/00; C07D285/01; C07D285/02; C07D285/04; C07D285/12; C07D285/125; C07D285/135; A; A61; A61K; A61K31/00; A61K31/16; A61K31/18; A61K31/33; A61K31/395; A61K31/41
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
113 words
A method of topically treating glaucoma with eye drops to reduce intraocular eye pressure, said method comprising: topically applying to the eye, a small but intraocular eye pressure reducing amount of a non-classical carbonic anhydrase inhibitor of the formula: ##STR3## wherein "R" is selected from the group consisting of substituted benzothiazole, 2-acylamino-1,3,4 thiadiazole-5-, 2-acylamino-2-methyl-1,3,4-thiadiazole-5, and dichloro-phenyl-1,3-di-; and X is selected from the group of hydrogen and hydroxyl, and Y is selected from the group of C 1 to C 6 alkyl and hydrogen, and if either X or Y is hydrogen the other is not hydrogen; and "n" is either 1 or 2, in combination with an inert, non-irritating, non-toxic eye drop diluent.
Claim 2
Independent Claim
113 words
A method of topically treating glaucoma with eye drops to reduce intraocular eye pressure, said method comprising: topically applying to the eye, a small but intraocular eye pressure reducing amount of a non-classical carbonic anhydrase inhibitor of the formula: ##STR3## wherein "R" is selected from the group consisting of substituted benzothiazole, 2-acylamino-1,3,4 thiadiazole-5-, 2-acylamino-2-methyl-1,3,4-thiadiazole-5, and dichloro-phenyl-1,3-di-; and X is selected from the group of hydrogen and hydroxyl, and Y is selected from the group of C 1 to C 6 alkyl and hydrogen, and if either X or Y is hydrogen the other is not hydrogen; and "n" is either 1 or 2, in combination with an inert, non-irritating, non-toxic eye drop diluent.
Claim 3
Dependent Claim
28 words
The method of claim 1 wherein said inhibitor is present at a concentration of from about 0.25% to about 5.0% by weight of said inhibitor and diluent combination.
Claim 4
Dependent Claim
20 words
The method of claim 2 wherein the dosage for topical application is three drops, with one drop every two minutes.
Claim 5
Dependent Claim
14 words
The method of claim 1 wherein the non-classical carbonic anhydrase inhibitor is methyl acetazolamide.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-11-20 | 1988-05-21 | 1988-11-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-11-20 | 1992-05-21 | 1992-11-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-11-20 | 1996-05-21 | 1996-11-20 | $7700.00 | Window Closed / Lapsed |